Concurrent lupus nephritis and Graves' disease improved with combined immunosuppression and methimazole in a single caseCase Report Shows Treatment for Concurrent Lupus and Graves Disease

Frontiers in Medicine Published October 29, 2026 Study authors: Xichang Wang, Xiaoguang Shi, Beiru Zhang, Mi Tian DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Recognize the lack of guidelines for concurrent lupus nephritis and Graves' disease; individualize therapy.

This is a single case report of a 39-year-old male with biopsy-proven ISN/RPS Class IV + V lupus nephritis and concurrent Graves' disease. The patient was treated with a combination of glucocorticoids, mycophenolate mofetil, and hydroxychloroquine for lupus nephritis, along with methimazole for Graves' disease and symptomatic therapy including antihypertensive and heart rate controlling agents.

The report notes early clinical and laboratory improvement. No effect size, absolute numbers, or statistical measures were reported. The authors state that limited follow-up precluded assessment of an established renal response.

No adverse events, serious adverse events, discontinuations, or tolerability data were reported. Funding and conflicts of interest were not reported.

The authors highlight the lack of authoritative guidelines or expert consensus for managing cases of concurrent lupus nephritis and Graves' disease. This case report provides only descriptive, single-patient observations and cannot establish efficacy or causality. Clinicians should interpret the findings as hypothesis-generating and recognize the need for individualized management in the absence of guideline guidance.

How this fits prior evidence

This case report addresses a gap noted in prior coverage: the absence of authoritative guidance for concurrent autoimmune conditions. Prior items described immune-mediated comorbidities in MS and irAEs from checkpoint inhibitors, but those sources could not define causality or prognostic impact. Similarly, this report offers only single-patient descriptive observations without comparative data. It does not confirm or extend prior findings on autoimmune comorbidity management, but it illustrates the clinical challenge of overlapping autoimmune diseases and the reliance on individualized therapy when guidelines are lacking.

A single case report describes the treatment of a 39-year-old man diagnosed with both lupus nephritis and Graves disease. Because there are currently no official guidelines or expert consensus for managing these two conditions at the same time, this case provides a look at how doctors managed the patient's specific needs.

The patient received a combination of glucocorticoids, mycophenolate mofetil, and hydroxychloroquine to treat the lupus nephritis. To manage the Graves disease, the patient was given methimazole. The patient also received medications to control heart rate and blood pressure. These treatments led to early clinical and laboratory improvements.

Because this was a single case report with a limited follow-up period, the results are not enough to prove a standard of care. The study could not determine if the patient achieved a long-term, established renal response. This report highlights the complexity of treating patients with multiple autoimmune conditions simultaneously.

What this means for you:

This single case shows early improvement for a patient with both lupus nephritis and Graves disease.

Common questions

What medications were used for this patient?

The patient received a combination of glucocorticoids, mycophenolate mofetil, and hydroxychloroquine for his lupus nephritis. To treat his Graves disease, he was given methimazole. He also received medications to control his heart rate and blood pressure.

Was the treatment effective for the patient?

The report showed early clinical and laboratory improvement for the patient. However, because the follow-up period was limited, the doctors could not determine if the patient achieved a long-term, established renal response.

Is there a standard way to treat both conditions at once?

Currently, there is a lack of authoritative guidelines or expert consensus for managing cases where a patient has both lupus nephritis and Graves disease at the same time. This case report provides one example of how a patient was treated.

Study Details

Study typeGuideline

EvidenceLevel 5

PublishedOct 2026

View Original Abstract ↓

Hyperthyroidism and systemic lupus erythematosus (SLE) are both common diseases in internal medicine. Among them, Graves’ disease (GD) is the most frequent cause of hyperthyroidism, while lupus nephritis (LN) represents one of the most severe organ manifestations of SLE. Basic research suggests that GD and SLE may share overlapping genetic and immunological pathways; however, whether these shared mechanisms contribute to their clinical coexistence remains uncertain. Clinical studies or case reports on their coexistence are currently limited, and we cannot effectively manage cases of co-occurrence based on authoritative guidelines or expert consensus. In this study, we report a 39-year-old male patient with biopsy-proven ISN/RPS Class IV + V LN concomitant with GD. The patient was treated with a combination of glucocorticoids, mycophenolate mofetil, and hydroxychloroquine for LN, along with methimazole for GD, supplemented by symptomatic therapy including antihypertensive and heart rate controlling agents, etc. The patient demonstrated early clinical and laboratory improvement during follow-up, although the limited follow-up precluded assessment of an established renal response.

Concurrent lupus nephritis and Graves' disease improved with combined immunosuppression and methimazole in a single caseCase Report Shows Treatment for Concurrent Lupus and Graves Disease

How this fits prior evidence

Common questions

Study Details

Evaluating the Efficacy of Traditional Chinese Medicine Decoctions for Rheumatoid Arthritis Management

Traditional Chinese medicine decoctions may improve rheumatoid arthritis symptoms

Clinical research that matters. Delivered to your inbox.

Concurrent lupus nephritis and Graves' disease improved with combined immunosuppression and methimazole in a single caseCase Report Shows Treatment for Concurrent Lupus and Graves Disease

How this fits prior evidence

Common questions

More on Systemic Lupus Erythematosus

Study Details

Evaluating the Efficacy of Traditional Chinese Medicine Decoctions for Rheumatoid Arthritis Management

Traditional Chinese medicine decoctions may improve rheumatoid arthritis symptoms

Clinical research that matters. Delivered to your inbox.

Related in Rheumatology

From Other Specialties